



Socioeconomic

Population¹

175 686 900 (2025)

Life expectancy at birth²

75.2 years (2025)

GDP/capita (current US\$)³



US\$ 2675 (2024)



Spending on health

Current health expenditure
(CHE)/capita (current US\$)⁴

US\$ 61 (2022)

2.39% (2022)
Current health
expenditure as share
of GDP⁵6.48% (2022)
Government health
expenditure (% of CHE)⁶
72.53% (2022)
Out-of-pocket
expenditure (% of CHE)⁴



Spending on pharmaceuticals

Government pharmaceutical
expenditure⁷

373.5 billion Taka

Government pharmaceutical
expenditure/capita

No data

54%
Pharmaceutical
expenditure (% of CHE)⁸50% (2022)
Share of out-of-pocket
expenditure on
pharmaceuticals⁸

Medical and pharmacy workforce

Medical doctors/
10 000 population⁹

7.22 (2023)

Pharmacists/
10 000 population⁹

1.1 (2023)

Pharmacy education
accreditation

Yes

Continuing professional
development for pharmacists

No



Pharmaceutical legislation and policy

1940 ● Drugs Act

1946 ● Bengal Drug Rule

1982 ● National Drug Policy;
Drug (Control) Ordinance

2005 ● National Drug Policy

2013 ● National Immunization Policy

2016 ● National Drug Policy

2017–2022 ● National Action Plan on AMR Containment

2023 ● Drugs and Cosmetics Act

2023–2028 ● National Action Plan on AMR Containment



Intellectual property rights



TRIPS flexibilities
incorporated into
the law



TRIPS flexibilities
utilized

2023

The Patent Act



Rational use and antimicrobial resistance

% of market share of
non-EML products

No data

WHO Global Antimicrobial Resistance and
Use Surveillance System enrollment¹⁰:
Yes, 2020

Total consumption of antibiotics¹¹:
2 024 309 575 DDD

FDC sales in the
private market

No data

Number of antibiotics on the private market¹²

	Total	AWaRe			Not recommended
		Access	Watch	Reserve	
Single drugs	65	22	36	7	-
FDCs	9	3	2	0	4

Market
entry

National Regulatory Authority

Directorate General of Drug Administration (DGDA)

Website: <https://dgda.portal.gov.bd/>Staff¹³: 424Annual budget¹³: US\$ 3.54 million

Products regulated

☒ Medicines¹⁴☒ Biologicals¹⁴☒ Medical
devices¹⁴☒ Traditional
medicines¹⁴

Licensing of establishments

☒ Manufacturers☒ Importers☒ Exporters☒ Wholesellers☒ Distributors☒ Retailers

National Medicines Quality Control Laboratory

1

☒ ISO 17025
certified☒ WHO
prequalifiedRational
selectionBody responsible for selection of medical products¹⁵

Directorate General of Drug Administration (DGDA)

☐ HTA used in the selection process☐ NEML incorporated AWaRE list☐ Medicines listed by level of care☒ Traditional medicines included

National Essential Medicines List (number of active ingredient)

2008

209 medicines

2016

Allopathic: 285; Ayurvedic: 98; Unani: 223

National Medicines Formulary¹⁶

2015

2019

National Essential Diagnostics List: No

Purchasing



Public sector

☒ Procurement: Decentralized

Agency responsible for procurement: No data

LMIS used: eLMIS

Frequency of tender: As required

Private sector

☒ Social Health Insurance

Name of SHI scheme¹⁷: Shastho Surokhsma Karmasuchi

Population coverage: No data

Number of products covered: No data

Pricing regulation



Pricing regulatory authority

Directorate General of Drug Administration (DGDA)

Public sector

Tendering¹⁸: Yes

Private sector

Maximum retail price: Yes

Number of price controlled products¹⁹: 117 medicines



Market distribution



Estimated pharmaceutical market value

US\$ 2.7 billion

Public

Tertiary hospitals²⁰: 64

Secondary hospitals²⁰: 205

PHC facilities²⁰: 16 247

Private

Manufacturers¹³: 275

Importers: 351

Wholesellers/distributors²¹: 2695

Retail pharmacies¹³: 264 908

Market exit



Legal provision for

☒ Cancellation of licences of pharmaceutical establishments²²

☒ Cancellation of marketing authorization of products²³

☒ Initiating product recalls and withdrawals

References

1. United Nations, Data Portal, Population Division, <https://population.un.org/dataportal/data/indicators/49/locations/50/start/2000/end/2025/table/pivotbylocation? df=96e66d1b-4c28-401d-aa6d-f5dfc5c15d08>, accessed 15 August 2025.
2. United Nations, Data Portal, Population Division, Life expectancy at birth, <https://population.un.org/dataportal/data/indicators/61/locations/50/start/2000/end/2025/table/pivotbylocation? df=718d48f4-96e3-4c53-acf6-4710d4b61256>, accessed 15 August 2025.
3. Bangladesh Economic Review 2024, <https://mof.portal.gov.bd/site/page/28ba57f5-59ff-4426-970a-bf014242179e/Bangladesh-Economic-Review>, accessed 15 August 2025.
4. World Health Organization, Global Health Expenditure database, Current Health Expenditure (CHE) per capita, <https://www.who.int/data/gho>, accessed 15 August 2025.
5. World Bank, Current Health Expenditure (% of GDP), <https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS>, accessed 15 August 2025.
6. World Health Organization, Global Health Expenditure database, Domestic General Government Health Expenditure as % of CHE, <https://apps.who.int/nha/database/ViewData/Indicators/en>, accessed 15 August 2025.
7. World Health Organization, Health Economics Unit, Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, Bangladesh Pharmaceutical Expenditure Tracking by Diseases, https://extranet.who.int/uhcpartnershiplivemonitoring/system/files/doc_attachments/Pharmaceutical%20Expenditure_Tracking_report.pdf, accessed 15 August 2025.
8. Bangladesh Bureau of Statistics, Household Income and Expenditure Survey (HIES) 2022, https://bbs.portal.gov.bd/sites/default/files/files/bbs.portal.gov.bd/page/b343a8b4_956b_45ca_872f_4cf9b2f1a6e0/2023-06-25-15-38-202e9c9b8eed1a7d9d7f08c30090164d.pdf, accessed 15 August 2025.
9. World Health Organization, Global Health Observatory, Health Workforce, <https://www.who.int/data/gho/data/themes/topics/health-workforce>, accessed 14 August 2025.
10. World Health Organization, Global Antimicrobial Resistance and Use Surveillance System (GLASS), <https://www.who.int/initiatives/glass/country-participation>, accessed 15 August 2025.
11. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report. Antibiotic use data for 2022. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO, <https://iris.who.int/bitstream/handle/10665/381094/9789240108127-eng.pdf?sequence=1>, accessed 16 August 2025.
12. Reported by the Directorate General of Drug Administration (DGDA), internal communication.
13. Directorate General of Drug Administration, <https://www.dgdagov.info/index.php>, accessed 15 August 2025.
14. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2019, <https://www.who.int/publications/i/item/9789290227281>, accessed 15 August 2025.
15. Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, <https://dgda.portal.gov.bd/>, accessed 18 August 2025.
16. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2023, <https://iris.who.int/handle/10665/373774>, accessed 15 August 2025.
17. Oxford Policy Management, Supporting the piloting of social health protection in Bangladesh, <https://www.opml.co.uk/projects/technical-assistance-piloting-social-health-protection-bangladesh>, accessed 15 August 2025.
18. World Health Organization, Medicines' price regulatory interventions in the WHO South-East Asia Region: Policy review and recommendations for further research, https://cdn.who.int/media/docs/default-source/searo/hsd/edm/medicines-price-regulatory-interventions-in-the-who-south-east-asiaregion-policy-review-and-recommendations-for-further-research.pdf?sfvrsn=5ff3b867_1&download=true, accessed 15 August 2025.
19. Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, <http://www.dgdagov.info/index.php/information-center/guidance-documents/1128-primary-healthcare-list/file>, accessed 15 August 2025.
20. Directorate General of Health Services, <http://hospitaldghs.gov.bd/introduction/>, accessed 15 August 2025.
21. Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, Whole Sale Pharmacy List, <http://www.dgdagov.info/index.php/pharmacies/whole-sale-pharmacy>, accessed 15 August 2025.
22. Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, Market Surveillance & Control, <http://dgdagov.info/index.php/information-center/market-surveillance-control/regulatory-actions/2306-regulatory-action-against-sfmedical-product/file>, accessed 15 August 2025.
23. Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh, Market Surveillance & Control, Regulatory actions, <http://dgdagov.info/index.php/information-center/market-surveillance-control/regulatory-actions>, accessed 15 August 2025.